Compare Meta Platforms Inc (META) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Moderna, Inc. — how do they compare? Meta Platforms Inc trades at $722.5 (market cap $1.84T), while Moderna, Inc. trades at $196.07 (market cap $78.65B). The key difference: Meta Platforms Inc is far larger — about 23.4× Moderna, Inc.'s market cap, and Meta Platforms Inc pays a 0.29% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Moderna, Inc. for 59 Days on average.
| META | MRNA | |
|---|---|---|
Market Cap | $1.84T | $78.65B |
Volume | 15,887,049 | 37,373,437 |
Sector | Media | Health |
52-Week High | $777.59 | $203.46 |
52-Week Low | $525.72 | $22.36 |
Typical Hold Time | 127 Days | 59 Days |
Enterprise Value | $1.86T | $74.80B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $719 and resistance at $726. Fundamentally, revenue grew to $200.97B in 2025 with a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a legal ruling on a youth addiction lawsuit in Massachusetts.
The outlook for META remains positive with strong analyst support—80% recommend Buy and a consensus price target of $781.00—driven by AI innovation and revenue growth. However, risks include regulatory challenges and high capital expenditures. Investors should weigh robust profitability against legal and competitive pressures in the social media and AI sectors.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
